FLORetina 2025: Industry advances front and center at FLORetina Congress

The upcoming The FLORetina International Congress on OCT Angiography, En Face OCT, and Advances in OCT (FLORetina-ICOOR) in Florence, Italy, is hosting 57 exhibitors who will showcase their latest technologies from 4 through 7 December.

Here are just a few of the technologic offerings and educational opportunities that are anticipated from the exhibitors.

Zeiss at FLORetina 2025

The company’s new Retina Workflow assists with all aspects of retinal care from diagnosis through management, monitoring, and in-office and surgical intervention. The platform combines imaging and patient history with interactive analysis.

The latest additions to the platform include artificial intelligence (AI)-guided optical coherence tomography (OCT) and ultra-widefield fundus imaging for enhanced diagnostic confidence.

Zeiss also has focused the spotlight on its Cirrus PathFinder, which facilitates AI-guided OCT image assessment.

The technology is described as “a fully integrated deep-learning, AI-based support tool that enables more confident decision-making with OCT interpretation assistance.” The technology streamlines the review of macular OCT scans by automatically identifying scans that may need closer review.

The ARTEVO 850 provides customizable 3D digital visualization and color 3D imaging. The Digital Color Assistant (DCA) component supports a view of the surgical field with digital color coding to accentuate the anatomic details. Surgeons have a choice of using either the preset color configurations optimized for specific procedures or their own customized digital color setting. Surgeons can observe surgical maneuvers in retinal tissue. The integrated intraoperative OCT allows real-time viewing of transparent ocular structures, thus facilitating monitoring of the surgical process and decision-making intraoperatively.

The TDC Veloce high-speed cutter offers improved aspiration flow compared with the previous generation for decreased surgical time, a cut speed of 20,000 cuts/minute to reduce tissue traction and increase efficiency, increased shaft stiffness, and new ergonomics to enhance comfort.

The instrument enables “SMART IOP” [intraocular pressure] for posterior surgery to compensate for pressure losses. According to the company, it adjusts the irrigation/infusion pressure to maintain a constant IOP during surgery and improved stability during procedures.

Alcon at FLORetina 2025

Alcon is introducing Valeda PBM, the first approved treatment for dry age-related macular degeneration.

On Saturday, 6 December, from 13:15 to 14:00, speakers will discuss the treatment during the following presentations in the San Giovanni Room:

Photobiomodulation Mechanism of Action and Effect

13:15 - 13:25

Speaker: Giuseppe Querque (Italy)

Clinical Findings from the LIGHTSITE III Trials

13:25 - 13:35

Speaker: Allen Ho (USA)

Anatomical and Imaging Findings of the LIGHTSITE III Trials

13:35 - 13:45

Speaker: Marion Munk (Switzerland)

Real-World Clinical Insights with Valeda

13:45 - 13:55

Speaker: Stratos Gotzaridis (Greece)

Panel Discussion

13:55 - 14:00

All speakers

Alcon is also sponsoring a presentation on Achieving Superior Efficiency in Vitreoretinal Surgery on December 5 from 12:30 to 13:15 CET. Stanislao Rizzo (Italy) will moderate. The venue is the Santa Maria Novella Room.

Attendees also can explore Alcon’s Unity VCS/CS at the company’s booth (#52). The Unity VCS platform is described by Alcon as the first and only platform delivering innovations for vitreoretinal and cataract surgery.

Another highlight will be the Alcon Sponsored Live Surgeries broadcast from France, UK, Germany, Japan, and Italy that will run from 4 to 6 December from 8:30 to 19:00 (UTC+01:00)

The surgeries can be viewed in the Santa Maria Novella Room.

RetinSight GmbH at FLORetina 2025

The company’s AI solutions provide diagnostic and therapeutic care for individuals at risk of retinal diseases. The company will be exhibiting at booth 35.

RetinSight offers their geographic atrophy (GA) monitor that facilitates disease assessment and evaluation of the effects of treatment.

A fluid monitor uses AI to quantitate fluid and the treatment response.

ONL Therapeutics at FLORetina 2025

The company is planning to present on “Advancing Geographic Atrophy Treatment with ONL1204 (xelafaslatide): Insights from the Phase 1b Study and Phase 2 Launch.”

Xelafaslatide (ONL1204) is a treatment for geographic atrophy (GA) that is designed to protect retinal cells from apoptosis.

Baruch D. Kuppermann, MD, PhD, Chair, Department of Ophthalmology, Director, Gavin Herbert Eye Institute, University of California, Irvine, will present on Saturday, 6 December at 4:29 p.m. CET in the San Giovanni Room.